Tonix Pharmaceuticals Holding Corp. and Massachusetts General Hospital have announced an agreement to evaluate TNX-1900 as a potential treatment for patients with binge eating disorder.
According to a press release, the investigator-initiated phase 2 clinical trial, which is expected to launch in the second half of 2022, will be a randomized, double-blind, placebo-controlled study of 60 patients diagnosed with both binge eating disorder and obesity.
Over the course of the 8-week study, TNX-1900 will be evaluated for efficacy and safety, and to determine whether it reduces frequency of bingeing